Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer.

Barton VN, Christenson JL, Gordon MA, Greene LI, Rogers TJ, Butterfield K, Babbs B, Spoelstra NS, D'Amato NC, Elias A, Richer JK.

Cancer Res. 2017 Jul 1;77(13):3455-3466. doi: 10.1158/0008-5472.CAN-16-3240. Epub 2017 May 16.

2.

MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.

Christenson JL, Butterfield KT, Spoelstra NS, Norris JD, Josan JS, Pollock JA, McDonnell DP, Katzenellenbogen BS, Katzenellenbogen JA, Richer JK.

Horm Cancer. 2017 Apr;8(2):69-77. doi: 10.1007/s12672-017-0285-6. Epub 2017 Feb 13.

3.

Constitutive expression of microRNA-150 in mammary epithelium suppresses secretory activation and impairs de novo lipogenesis.

Heinz RE, Rudolph MC, Ramanathan P, Spoelstra NS, Butterfield KT, Webb PG, Babbs BL, Gao H, Chen S, Gordon MA, Anderson SM, Neville MC, Gu H, Richer JK.

Development. 2016 Nov 15;143(22):4236-4248. Epub 2016 Oct 11.

4.

Cooperative Dynamics of AR and ER Activity in Breast Cancer.

D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK.

Mol Cancer Res. 2016 Nov;14(11):1054-1067. Epub 2016 Aug 26.

5.

Dicer expression in estrogen receptor-positive versus triple-negative breast cancer: an antibody comparison.

Spoelstra NS, Cittelly DM, Christenson JL, Gordon MA, Elias A, Jedlicka P, Richer JK.

Hum Pathol. 2016 Oct;56:40-51. doi: 10.1016/j.humpath.2016.05.014. Epub 2016 May 31.

6.

A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.

D'Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, Nemkov TG, D'Alessandro A, Hansen KC, Richer JK.

Cancer Res. 2015 Nov 1;75(21):4651-64. doi: 10.1158/0008-5472.CAN-15-2011. Epub 2015 Sep 11.

7.

Narrow Band Ultraviolet B Treatment for Human Vitiligo Is Associated with Proliferation, Migration, and Differentiation of Melanocyte Precursors.

Goldstein NB, Koster MI, Hoaglin LG, Spoelstra NS, Kechris KJ, Robinson SE, Robinson WA, Roop DR, Norris DA, Birlea SA.

J Invest Dermatol. 2015 Aug;135(8):2068-2076. doi: 10.1038/jid.2015.126. Epub 2015 Mar 30.

8.

Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.

Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK.

Mol Cancer Ther. 2015 Mar;14(3):769-78. doi: 10.1158/1535-7163.MCT-14-0926. Epub 2015 Feb 23.

9.

Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.

Niemeyer BF, Parrish JK, Spoelstra NS, Joyal T, Richer JK, Jedlicka P.

PLoS One. 2015 Jan 20;10(1):e0116895. doi: 10.1371/journal.pone.0116895. eCollection 2015. Erratum in: PLoS One. 2015;10(3):e0120830.

10.

Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b.

Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, Howe EN, Edgerton SM, Anderson SM, Thor AD, Richer JK.

Horm Cancer. 2014 Dec;5(6):374-89. doi: 10.1007/s12672-014-0188-8. Epub 2014 Sep 12.

11.

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.

Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK.

Breast Cancer Res. 2014 Jan 22;16(1):R7. doi: 10.1186/bcr3599.

12.

Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.

Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK.

Mol Cancer Ther. 2012 Dec;11(12):2556-65. doi: 10.1158/1535-7163.MCT-12-0463. Epub 2012 Oct 16.

13.

Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.

Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK.

Oncogene. 2013 May 16;32(20):2555-64. doi: 10.1038/onc.2012.275. Epub 2012 Jul 2.

14.

The role of miRNAs in progesterone action.

Cochrane DR, Spoelstra NS, Richer JK.

Mol Cell Endocrinol. 2012 Jun 24;357(1-2):50-9. doi: 10.1016/j.mce.2011.09.022. Epub 2011 Sep 17. Review.

PMID:
21952083
15.

MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer.

Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK.

Horm Cancer. 2010 Dec;1(6):306-19. doi: 10.1007/s12672-010-0043-5.

16.

Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.

Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE.

Mol Cancer. 2010 Dec 20;9:317. doi: 10.1186/1476-4598-9-317.

17.

Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers.

Cochrane DR, Howe EN, Spoelstra NS, Richer JK.

J Oncol. 2010;2010:821717. doi: 10.1155/2010/821717. Epub 2009 Dec 15.

18.

MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents.

Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK.

Mol Cancer Ther. 2009 May;8(5):1055-66. doi: 10.1158/1535-7163.MCT-08-1046. Epub 2009 May 12.

19.

Gene expression profiling of multiple leiomyomata uteri and matched normal tissue from a single patient.

Dimitrova IK, Richer JK, Rudolph MC, Spoelstra NS, Reno EM, Medina TM, Bradford AP.

Fertil Steril. 2009 Jun;91(6):2650-63. doi: 10.1016/j.fertnstert.2008.03.071. Epub 2008 Jul 30.

20.

ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease.

Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus RR, Richer JK.

Mod Pathol. 2008 Jul;21(7):912-23. doi: 10.1038/modpathol.2008.82. Epub 2008 May 16.

21.

Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance.

Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK.

Breast Cancer Res Treat. 2008 Dec;112(3):475-88. doi: 10.1007/s10549-008-9897-4. Epub 2008 Mar 9.

PMID:
18327671
22.

Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes.

Harrell JC, Dye WW, Allred DC, Jedlicka P, Spoelstra NS, Sartorius CA, Horwitz KB.

Cancer Res. 2006 Sep 15;66(18):9308-15.

23.

Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: Correlation with clinicopathologic parameters and biomarkers.

Balmer NN, Richer JK, Spoelstra NS, Torkko KC, Lyle PL, Singh M.

Mod Pathol. 2006 Dec;19(12):1593-605. Epub 2006 Sep 15.

24.

The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers.

Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh M, Shroyer KR, Broaddus RR, Horwitz KB, Richer JK.

Cancer Res. 2006 Apr 1;66(7):3893-902.

25.

Effect of dietary energy restriction on vascular density during mammary carcinogenesis.

Thompson HJ, McGinley JN, Spoelstra NS, Jiang W, Zhu Z, Wolfe P.

Cancer Res. 2004 Aug 15;64(16):5643-50.

26.

Targeting angiogenesis for mammary cancer prevention: factors to consider in experimental design and analysis.

Thompson HJ, McGinley JN, Wolfe P, Spoelstra NS, Knott KK.

Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1173-84.

27.

Vascular density profile of rat mammary carcinomas induced by 1-methyl-1-nitrosourea: implications for the investigation of angiogenesis.

Thompson HJ, McGinley JN, Knott KK, Spoelstra NS, Wolfe P.

Carcinogenesis. 2002 May;23(5):847-54.

PMID:
12016159

Supplemental Content

Loading ...
Support Center